| Title : Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders - Mathew_2021_Environ.Sci.Pollut.Res.Int__1 |
| Author(s) : Mathew B , Oh JM , Baty RS , Batiha GE , Parambi DGT , Gambacorta N , Nicolotti O , Kim H |
| Ref : Environ Sci Pollut Res Int , :1 , 2021 |
| Abstract : Mathew_2021_Environ.Sci.Pollut.Res.Int__1 |
| ESTHER : Mathew_2021_Environ.Sci.Pollut.Res.Int__1 |
| PubMedSearch : Mathew_2021_Environ.Sci.Pollut.Res.Int__1 |
| PubMedID: 33743158 |
| Title : Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases - Mathew_2019_Arch.Pharm.(Weinheim)__e1900177 |
| Author(s) : Mathew B , Parambi DGT , Mathew GE , Uddin MS , Inasu ST , Kim H , Marathakam A , Unnikrishnan MK , Carradori S |
| Ref : Arch Pharm (Weinheim) , :e1900177 , 2019 |
| Abstract : Mathew_2019_Arch.Pharm.(Weinheim)__e1900177 |
| ESTHER : Mathew_2019_Arch.Pharm.(Weinheim)__e1900177 |
| PubMedSearch : Mathew_2019_Arch.Pharm.(Weinheim)__e1900177 |
| PubMedID: 31478569 |
| Title : Cholinesterase Inhibitory Activities of Selected Halogenated Thiophene Chalcones - Parambi_2019_Cent.Nerv.Syst.Agents.Med.Chem_19_67 |
| Author(s) : Parambi DGT , Aljoufi F , Murugaiyah V , Mathew GE , Dev S , Lakshminarayanan B , Hendawy OM , Mathew B |
| Ref : Cent Nerv Syst Agents Med Chem , 19 :67 , 2019 |
| Abstract : Parambi_2019_Cent.Nerv.Syst.Agents.Med.Chem_19_67 |
| ESTHER : Parambi_2019_Cent.Nerv.Syst.Agents.Med.Chem_19_67 |
| PubMedSearch : Parambi_2019_Cent.Nerv.Syst.Agents.Med.Chem_19_67 |
| PubMedID: 30451121 |
| Title : Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review - Mathew_2019_CNS.Neurol.Disord.Drug.Targets_18_432 |
| Author(s) : Mathew B , Parambi DGT , Sivasankarapillai VS , Uddin MS , Suresh J , Mathew GE , Joy M , Marathakam A , Gupta SV |
| Ref : CNS Neurol Disord Drug Targets , 18 :432 , 2019 |
| Abstract : Mathew_2019_CNS.Neurol.Disord.Drug.Targets_18_432 |
| ESTHER : Mathew_2019_CNS.Neurol.Disord.Drug.Targets_18_432 |
| PubMedSearch : Mathew_2019_CNS.Neurol.Disord.Drug.Targets_18_432 |
| PubMedID: 31187716 |